Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
Takeda Pharmaceutical Company Limited ("Takeda") (TOKYO:4502/NYSE:TAK) today announced that it has filed its Corporate Governance Report with the Tokyo Stock Exchange ("TSE") in accordance with the regulations* for TSE listed companies. The Report can be accessed on Takeda's website at: https://www.takeda.com/who-we-are/corporate-governance/.
This report is prepared based on the revised Corporate Governance Code as in effect as of June 11, 2021. It describes the latest corporate governance features of our Company, including the new structure of the Board of Directors after the 146th General Shareholder's Meeting held on June 29, 2022.
Key elements of Takeda's Corporate Governance Report:
Takeda aims for increased transparency and objectivity of the Board of Directors by maintaining the high composition ratio of Independent External Directors (4 Internal Directors and 11 Independent External Directors) and having an independent external director serve as the Chair of the Board meeting.
The Board of Directors is composed of diverse members with various background, experiences and knowledge (BOD Skill Matrix), to help enable strategic discussions and effective supervision of the Company.
The Audit and Supervisory Committee, and the Nomination/Compensation Committees as advisory committees for the Board of Directors are composed entirely of Independent External Directors, including each head/chairperson, in order to ensure the independence of each committee.
Internal directors receive a certain level of delegation of authority from the Board of Directors, and the Takeda Executive Team, which is diverse in terms of background, nationality, gender, and age, ensures agile and efficient decision-making based on strategic discussions at the management committee meetings.
Takeda's latest Corporate Governance Report can be found at the information disclosure site operated by the Japan Exchange Group which consists of the TSE and other exchanges in Japan at:
https://www2.jpx.co.jp/tseHpFront/CGK020010Action.do?Show=Show
Takeda also furnished the English version of the Corporate Governance Report with the U.S. Securities and Exchange Commission (the "SEC"), available at www.sec.gov.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
Quest Diagnostics , a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on July 22, 2024 to shareholders of record of Quest Diagnostics common stock...
Veracyte, Inc. a leading cancer diagnostics company, today announced it will participate in the following investor conferences.
Leerink Partners 2024 Healthcare Crossroads Conference ? Austin, TX
Fireside Chat on May 29th at 12:20 p.m. Eastern...
Extendicare Inc. ("Extendicare" or the "Company") today reported results for the three months ended March 31, 2024. Results are presented in Canadian dollars unless otherwise noted. First Quarter 2024 Highlights Adjusted EBITDA(1) excluding...
Quipt Home Medical Corp. (the "Company") , a U.S.-based home medical equipment provider, focused on end-to-end respiratory care, today announced its second quarter fiscal 2024 financial results and operational highlights. These results pertain to the...
The Friends of the Uniformed Services University (Friends of USU) will host a lunch and panel discussion on Wednesday, May 22, 12:00-2:30 p.m. at the National Press Club in Washington, DC., to discuss the history, present state, and future of...
Enhancing opportunities for family connection and enrichment on vacation and beyond, the family-friendly Beaches Resorts joins global impact nonpro?t organization and longtime partner, Sesame Workshop, to debut all-new programming designed to get...